Table 3 Neurotoxicity after induction therapy with bortezomib–dexamthasone (N=51—two patients could not be evaluated) and after high-dose melphalan with bortezomib and stem cell support (N=49)

From: Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

 

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

After induction (Btz-Dex)

 Neuropatic pain

43

7

0

1

0

 Sensory neuropathy

26

21

3

1

0

After HDM-Btz

 Neuropatic pain

45

0

2

2

0

 Sensory neuropathy

40

4

2

3

0

  1. Abbreviations: Btz-Dex=bortezomib–dexamethasone; HDM-Btz=bortezomib–high-dose melphalan.
  2. Neurotoxicity maximal grade (according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE), version 3.0 (http://ctep.cancer.gov/forms/CTCAEv3.pdf)).
Back to article page